Cancer Treatment Reviews
Volume 26, Issue 5 , Pages 377-391 , October 2000

Treatment-related leukaemia—a clinical and scientific challenge

  • A. Ng*

      Affiliations

    • Academic Unit of Paediatric Oncology, Christie and Manchester Children’s Hospitals Trusts, Manchester, M20 4BX, U.K.
    • ,
  • G.M. Taylor

      Affiliations

    • Immunogenetics Laboratory, St Mary’s Hospital, Hathersage Road, Manchester, M13 OJH, U.K.
    • ,
  • O.B. Eden

      Affiliations

    • Academic Unit of Paediatric Oncology, Christie and Manchester Children’s Hospitals Trusts, Manchester, M20 4BX, U.K.

References 

    REFERENCES
  1. Pedersen-Bjergaard J, Larsen SO. Incidence of acute non-lymphocytic leukemia, pre-leukemia and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin’s disease. N Engl J Med. 1982;307:965–971
  2. Valagnssa P, Santoro A, Fossati-Bellani F. Second acute leukemia and other malignancies following treatment for Hodgkin’s disease. J Clin Oncol. 1986;4:830–837
  3. Tucker MA, Coleman CN, Cox RS. Risk of second cancers after treatment for Hodgkin’s disease. N Engl J Med. 1988;318:76–81
  4. Meadows AT, Obringer AC, Marrero O. Second malignant neoplasms following childhood Hodgkin’s disease: treatment and splenectonmy as risk factors. Med Pediatr Oncol. 1989;17:477–484
  5. Kaldor JM, Day NE, Clarke EA. Leukemia following Hodgkin’s disease. N Engl J Med. 1990;322:7–13
  6. Sugita K, Tsuchida M, Nakazawa S. High frequency of etoposide (VP16) related secondary leukemia in children with non-Hodgkin’s lymphoma. Am J Pediatr Hematol Oncol. 1993;15:99–104
  7. Pui CH, Behm FG, Raimondi SC. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989;321:136–142
  8. Eden OB, Hann IM, Harrison C. Secondary acute myeloid leukemia in children treated for acute lymphoblastic leukemia. Blood. 1998;92:83a
  9. Felix CA, Blatt J. Etoposide and Langerhans cells histiocytosis; second malignancies, a second look. Ped Hematol Oncol. 1999;16:183–185
  10. Kushner B, Cheung NK, Kramer K. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol. 1998;16:3880–3889
  11. Moss TJ, Strauss LC, Das L. Secondary leukemia following successful treatment of Wilms’ tumour. Am J Pediatr Hematol Oncol. 1989;11:158–161
  12. Heyn R, Khan F, Ensign L. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study 3: an interim report. Med Ped Oncol. 1994;23:99–106
  13. Lesesve JF, Schneider P, Dolgopolov I. Therapy-related acute myeloid leukemia with t(8;21) in a child with previous Ewing’s sarcoma. Med Ped Oncol. 1997;29:132–134
  14. Kushner B, Heller G, Cheung NK. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumours. J Clin Oncol. 1998;16:3016–3020
  15. Farhi D, Odell C, Shurin SB. Myelodysplastic syndrome and acute myeloid leukemia after treatment for solid tumours of childhood. Am J Clin Pathol. 1993;100:270–275
  16. Pedersen-Bjergaard J, Hansen SW, Larsen SO. Increased risk of myelodysplasia and leukemia after etoposide, cisplatin and bleomycin for germ cell tumours. Lancet. 1991;338:359–363
  17. Schneider D, Hilgenfield E, Schwabe D. Acute myelogenous leukemia after treatment for malignant germ cell tumours in children. J Clin Oncol. 1999;17:3226–3233
  18. Kollmannsberger C, Beyer J, Droz JP. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumours. J Clin Oncol. 1998;16:3386–3391
  19. Boshoff C, Begent RH, Oliver RT. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol. 1995;6:35–40
  20. Albain KS, Le Beau MM, Ullirsch R. Implication of prior treatment with drug combinations including inhibitors of topoisomerase 2 in therapy-related monocytic leukemia with a 9;11 translocation. Genes Chromosomes Cancer. 1990;2:53–58
  21. Hawkins MM, Kinnier Wilson LM, Stovall MA. Epipodophyllotoxins, alkylating agents and radiation and risk of secondary leukaemia after childhood cancer. BMJ. 1992;304:951–958
  22. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risk. Med Ped Oncol. 1994;23:86–98
  23. Tucker MA, Meadows AT, Boice JD. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Instl. 1987;78:459–464
  24. Smith MA, Rubinstein L, Cazenave L. Report of the cancer therapy evaluation program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Natl Cancer Instl. 1993;85:554–558
  25. Kreissman SG, Gelber RD, Cohen HJ. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer. 1992;70:2208–2213
  26. Smith MA, McCaffrey RP, Karp JE. The secondary leukemias: challenges and research directions. J Natl Cancer Instl. 1996;88:407–418
  27. Pui CH, Ribeiro RC, Hancock ML. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682–1687
  28. Pui CH, Relling MV, Rivera GK. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia. 1995;9:1990–1996
  29. Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematology/Oncology Clinics North Am. 1996;10:293–320
  30. Winick NJ, McKenna RW, Shuster JJ. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol. 1993;11:209–217
  31. Park DJ, Koeffler HP. Therapy-related myelodysplastic syndromes. Sem Hematol. 1996;33:256–273
  32. Greene MH, Harris EL, Gershenson DM. Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med. 1986;105:360–367
  33. Sanderson BJ, Schield AJ. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res. 1996;355:41–57
  34. Kaina B. Critical steps in alkylation-induced aberration formation. Mutat Res. 1998;404:119–124
  35. Yarnold JR, Stratton M, McMillan TJ. Molecular Biology for Oncologist, 2nd Edn. London: Chapman and Hall,; 1996;
  36. Yarnold JR. Molecular aspects of cellular responses to radiotherapy. Radiotherapy Oncology. 1997;44:1–7
  37. Deininger MWN, Bose S, Gora-Tybor J. Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res. 1998;58:421–425
  38. Pui CH, Relling MV, Behm FG. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia. 1995;9:1680–1684
  39. Whitlock MD, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia. Cancer. 1991;68:600–604
  40. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochimica et Biophysica Acta. 1998;1400:233–255
  41. Felix CA, Hosler MR, Winick NJ. ALL-1 gene rearrangement in DNA topoisomerase 2 inhibitor-related leukemia in children. Blood. 1995;85:3250–3256
  42. Pedersen-Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase 2. Blood. 1991;78:1147–1148
  43. Quesnel B, Kantarjian H, Pedersen-Bjergaard J. Therapy-related acute myeloid leukemia with t(8;21), inv(16) and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol. 1993;11:2370–2379
  44. Liu LF, Liu CC, Alberts BM. Type 2 DNA-topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell. 1980;19:697–707
  45. Corbett AH, Zechiedrich EL, Osheroff N. A role for the passage helix in the DNA cleavage reaction of eukaryotic topoisomerase 2. A two-site model for enzyme-mediated DNA cleavage. J Biol Chem. 1992;267:683–686
  46. Berger JM, Wang JC. Recent developments in DNA topoisomerase 2 structure and mechanism. Curr Opin Struct Biol. 1996;6:84–90
  47. Berger JM, Fass D, Wang JC. Structural similarities between topoisomerases that cleave one or both DNA strands. Proc Natl Acad Sci USA. 1998;95:7876–7881
  48. Epstein RJ. Drug-induced DNA damage and tumour chemosensitivity. J Clin Oncol. 1990;8:2062–2084
  49. van Maanen JMS, Retel J, de Vries J. Mechanism of action of antitumour drug etoposide: a review. J Natl Cancer Instl. 1998;80:1526–1533
  50. Berger NA, Chatterjee S, Schmotzer JA. Etoposide (VP-16–213) induced gene alterations: potential contribution to cell death. Proc Natl Acad Sci USA. 1991;88:8740–8743
  51. Prommier Y, Orr A, Kohn K. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase 2 cleavage in the human c-myc protooncogene. Cancer Res. 1992;52:3125–3130
  52. Capranico G, Zunino F. DNA topoisomerase 2-trapping antitumour drugs. Eur J Cancer. 1992;28A:2055–2060
  53. Carrol J, Lavenir L, Impey H. An MLL–AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogene. Cell. 1996;85:853–861
  54. Lavan C, Szilvassy SJ, Slany R. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally-transduced HRX-ENL. EMBO J. 1997;16:4226–4237
  55. Megonigal MD, Rappaport EF, Nowell PC. Potential role for wild type p53 in leukemias with MLL gene translocations. Oncogene. 1998;16:1351–1356
  56. Felix CA, Hosler MR, Provisor D. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood. 1996;87:4376–4381
  57. Michels SD, McKenna RW, Arthur DC. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985;65:1364–1372
  58. Sandberg AA, Vuopio P. Secondary leukemias associated with neoplasia: treated and untreated. Cancer Genet Cytogenet. 1984;11:319–321
  59. Arthur DC, Bloomfield CD. Banded chromosome analysis in patients with treatment-associated acute non-lymphocytic leukemia. Cancer Genet Cytogenet. 1984;12:189–199
  60. Rubin CM, Arthur DC, Woods WG. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood. 1991;78:2982–2988
  61. Whang-Peng J, Young RC, Lee EC. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood. 1998;71:403–414
  62. Pedersen-Bjergaard J, Philip P, Larsen SO. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute non-lymphocytic leukemia. Blood. 1990;76:1083–1091
  63. Pedersen-Bjergaard J, Pedersen M, Roulston D. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86:3542–3552
  64. Rowley JD, Le Beau MM. Cytogenetic and molecular analysis of therapy-related leukemia. Annals N Y Acad Sci. 1989;567:130–140
  65. Le Beau MM, Epstein N, O’Brien S. The interleukin 3 gene is located on human chromosome 5 and is deleted in myeloid leukemias with a deletion of 5q. Proc Natl Acad Sci USA. 1987;84:5913–5917
  66. Le Beau MM, Lemons R, Espinosa R. Interleukin 4 and interleukin 5 map to human chromosome 5 in a region, encoding growth factors and receptors and are deleted in myeloid leukemias with a del(5q). Blood. 1989;73:647–650
  67. Le Beau MM, Espinosa R, Davis EM. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood. 1996;88:1930–1935
  68. Luna-Fineman S, Shannon KM, Lange BJ. Childhood monosomy 7: epidemiology, biology and mechanistic implications. Blood. 1995;85:1985–1999
  69. Vogelstein B, Civin CI, Preisinger AC. RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study. Genes Chromosomes Cancer. 1990;2:159–162
  70. Farr C, Gill R, Katz F. Analysis of RAS gene mutations in childhood myeloid leukemia. BJH. 1991;77:323–327
  71. Taylor J, Sandler D, Bloomfield C. RAS oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Instl. 1992;84:1626–1632
  72. Side L, Teel K, Wang P. Activating RAS mutations in therapy-related myeloid disorders associated with deletions of chromosomes 5 and 7. Blood. 1996;88:566a-[abstract]
  73. Johnston C, Morris J, Hall A. The role of RAS in signal transduction. Biochem Soc Trans. 1991;19:296–299
  74. Secker-Walker LM, Stewart EL, Todd A. Acute lymphoblastic leukemia with t(4;11) follows neuroblastoma: a late effect of treatment?. Med Ped Oncol. 1985;13:48–50
  75. Ratain MJ, Kaminer LS, Bitran JD. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non small-cell carcinoma of the lung. Blood. 1987;70:1412–1417
  76. Berger R, Kaneko Y. Fourth International Workshop on chromosomes in leukemia: rearrangement of 11q. Cancer Genet Cytogenet. 1982;11:294–295
  77. Prieto F, Palau F, Badia L. 11q23 abnormalities in children with acute non-lymphocytic leukemia (M4–M5). Association with previous chemotherapy. Cancer Genet Cytogenet. 1990;45:1–11
  78. Rubnitz JE, Behm FG, Downing JR. 11q23 rearrangements in acute leukemia. Leukemia. 1996;10:74–82
  79. Bernard O, Berger R. Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. Gene Chromosome Cancer. 1995;13:75–85
  80. Thirman MJ, Gill HJ, Burnett RC. Rearrangement of the MLL gene in acute lymphoblastic and myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med. 1993;329:909–914
  81. Hunger SP, Tkachuk DC, Amylon MD. HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities. Blood. 1993;81:3197–3203
  82. Super HJG, McCade NR, Thirman MJ. Rearrangement of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase 2. Blood. 1993;82:3705–3711
  83. Megonigal MD, Rappaport EF, Jones DH. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. Proc Natl Acad Sci USA. 1997;94:11583–11588
  84. Felix CA, Winick NJ, Negrini M. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia. Cancer Res. 1993;53:2954–2956
  85. Di Martino JE, Cleary ML. MLL rearrangements in haematological malignancies: lessons from clinical and biological studies. BJH. 1999;106:614–626
  86. Rasio D, Schichman SA, Negrini M. Complete exon structure of the ALL-1 gene. Cancer Res. 1996;56:1766–1769
  87. Mbangkollo D, Burnett R, McCabe N. The human MLL gene: nucleotide sequence, homology to the Drosophila TRX Zinc-finger domains and alternative splicing. DNA and cell Biology. 1995;14:475–483
  88. Felix CA, Hosler MR, Slater DJ. MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children. J Pediatr Hematol Oncol. 1998;20:299–308
  89. Carrol J, Forster A, Thompson S. Acute leukemias of different lineages have similar MLL gene fusions encoding related chimeric proteins resulting from chromosomal translocation. Proc Natl Acad Sci USA. 1993;90:8538–8542
  90. Keamey L, Bower M, Gibbons B. Chromosome 11q23 translocations in both infant and adult leukemias are detected by in situ hybridization with a yeast artificial chromosome. Blood. 1992;80:1659–1665
  91. Behm FG, Raimondi SC, Frestedt JL. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood. 1996;87:2870–2877
  92. Strissel Broeker PL, Super HG, Thirman MJ. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase 2 consensus binding sites. Blood. 1996;87:1912–1922
  93. Spitzner JR, Muller MT. A consensus sequence for cleavage by vertebrate DNA topoisomerase 2. Nucleic Acid Res. 1988;16:5533–5556
  94. Domer PH, Head DR, Renganathan N. Molecular analysis of 13 cases of MLL /11q23 secondary acute leukemia and identification of topoisomerase 2 consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with t(4;11). Leukemia. 1995;9:1305–1312
  95. Strissel Broeker PL, Strick R, Rowley JD. An in vivo topoisomerase 2 cleavage site and a DNase 1 hypersensitive site colocalise near exon 9 in theMLL breakpoint cluster region. Blood. 1998;92:3793–3803
  96. Aplan PD, Chervinsky DS, Stanulla M. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase 2 inhibitors. Blood. 1996;87:2649–2658
  97. Gu Y, Alder H, Nakamura T. Sequence analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia. Cancer Res. 1994;54:2327–2330
  98. Cimino G, Rapanotti MC, Biondi A. Infant acute leukemias show the same biased distribution of ALL-1 gene breaks as topoiomerase 2 related secondary acute leukemias. Cancer Res. 1997;57:2879–2883
  99. Ross JA, Potter JD, Reaman CH. Maternal exposure to potential inhibitors of DNA topoisomerase 2 and infant leukemia (US): a report from the Children’s Cancer Group. Cancer Causes Control. 1996;7:581–590
  100. Felix CA, Lange BJ. Leukemia in infants. Oncologist. 1999;4:225–240
  101. Felix CA, Lange BJ, Hosler MR. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase 2 cleavage sites. Cancer Res. 1995;55:4287–4292
  102. Rubnitz JE, Behm FG, Curcio-Brint AM. Molecular analysis of t(11;19) breakpoints in childhood acute leukemias. Blood. 1996;87:4804–4808
  103. Nakamura T, Alder H, Gu Y. Genes on chromosomes 4, 9 and 19 involved in 11q23 abnormalities in acute leukemias share sequence homology and/or common motifs. Proc Natl Acad Sci USA. 1993;90:4631–4635
  104. Tse W, Zhu W, Chen HS. A novel gene, AF1q, fused to MLL in t(1;11)(q21;q23), is specifically expressed in leukemic and immature haematopoietic cells. Blood. 1995;85:650–656
  105. Hillion J, Le Coniat M, Jonveaux P. AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. Blood. 1997;90:3714–3719
  106. Ida K, Kitabayashi I, Taki T. Adenoviral EIA-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood. 1997;90:4699–4704
  107. Sobulo OM, Borrow J, Tomek R. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA. 1997;94:8732–8737
  108. Rowley JD. The der(11) chromosome contains the critical breakpoint junction in the 4;11, 9;11 and 11;19 translocations in acute leukemia. Genes Chromosome Cancer. 1992;5:264–266
  109. Roulston D, Espinosa R, Rowley JD. CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood. 1998;92:2879–2885
  110. Stanulla M, Wang J, Chervinsky DS. Topoisomerase 2 inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus. Leukemia. 1997;11:490–496
  111. Downing JR. The AML-ETO transcription factor in acute myeloid leukemia: biology and clinical significance. BJH. 1999;106:296–308
  112. Pedersen-Bjergaard J, Johansson B, Philip P. Translocation (3;21)(q26;q22) in therapy-related myelodysplasia following drugs targeting DNA topoisomerase 2 combined with alkylating agents and in myeloproliferative disorders undergoing spontaneous leukemic transformation. Cancer Genet Cytogenet. 1994;76:50–55
  113. Davidson A, Gowing R, Lowis S. Phase 2 study of 21 day schedule oral etoposide in children. New Agent Group of the UKCCSG. Eur J Cancer. 1997;33:1816–1822
  114. Yagita M, leki Y, Onishi R. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer. Int J Oncol. 1998;13:91–96
  115. Ng A, Taylor GM, Eden OB. Secondary leukaemia in a child with neuroblastoma whilst on oral etoposide- what is the cause?. Pediatric Hematology Oncology. 2000;17:273–279
  116. Gills S, Sofer O, Zelig O. Acute promyelocytic leukemia with t(15;17) following treatment of Hodgkin’s disease- a report of 4 cases. Annals Oncol. 1995;6:777–779
  117. Detourmignies L, Castaigne S, Stoppa AM. Therapy-related acute promyelocytic leukemia: a report of 16 cases. J Clin Oncol. 1992;10:1430–1435
  118. Naoe T, Kudo K, Yoshida H. Molecular analysis of the t(15;17) translocation in de novo and secondary acute promyelocytic leukemia. Leukemia. 1997;11:287–288
  119. Rubnitz JE, Look T. Molecular genetics of childhood leukemias. J Pediatr Hematol Oncol. 1998;20:1–11
  120. Xue Y, Lu D, Guo Y. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leuk Res. 1992;16:1113–1223
  121. Dissing M, Le Beau MM, Pedersen-Bjergarrd J. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related DNA topoisomerase 2 inhibitors?. J Clin Oncol. 1998;16:1890–1896
  122. Rowley JD, Reshmi J, Sobulo O. All patients with the t(11;16)(q23;q13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood. 1997;90:535–541
  123. Borrow J, Stanton VP, Andresen M. The translocation t(8;160(p11;p13) of acute myeloid leukemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet. 1996;14:33–41
  124. Pedersen-Bjergaard J, Brondum-Nielsen K, Karle H. Chemotherapy-related and late-occurring Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase 2 inhibitors?. Leukemia. 1997;11:1571–1574
  125. Ahuja HG, Felix CA, Aplan PD. The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results inNUP98-TOP1 fusion. Blood. 1999;94:3258–3261
  126. Ikeda T, Ikeda K, Sasaki K. The inv(11)(p15q22) chromosome translocation of therapy-related myelodysplasia with NUP98-DDX10 and DDX10-NUP98 fusion transcripts. Int J Hematol. 1998;69:160–164
  127. Merlat A, Lai JL, Sterkers Y. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia. 1999;13:250–257
  128. Ben-Yehuda D, Krichevsky S, Caspi O. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood. 1996;88:4296–4303
  129. Sterkers Y, Preudhomme C, Lai JL. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion cases with 17p deletion. Blood. 1998;91:616–622
  130. Hunger SP, Sklar J, Link MP. Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: Report of 3 cases and review of literature. J Clin Oncol. 1992;10:156–163
  131. Draper GJ, Sandler BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53:661–671
  132. Birch JM. Genes and cancer. Arch Dis Child. 1999;80:1–3
  133. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome- a molecular and clinical review. Br J Cancer. 1997;76:1–14
  134. Felix CA, Megonigal MD, Chervinsky DS. Association of germ-line p53 mutation with MLL segmental jumping translocation in treatment-related leukemia. Blood. 1998;91:4451–4456
  135. Cuthbert G, McCullough S, Finney R. Jumping translocation at 11q23 with MLL gene rearrangement and interstitial telomeric sequences. Gene Chromosome Cancer. 1999;24:295–298
  136. Tanaka K, Arif M, Eguchi M. Frequent jumping translocations of chromosomal segments involving the ABL oncogene alone or in combination withCD3–MLL genes in secondary leukemias. Blood. 1997;89:596–600
  137. Maris JM, Wiersma SR, Mahgoub N. Monosomy 7 syndrome and other secondary neoplasms in children with NF1. Cancer. 1997;79:1438–1446
  138. Raunio H, Husgafvel-Pursiainen K, Anittila S. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility—a review. Gene. 1995;159:113–121
  139. Chen H, Sandler DP, Taylor JA. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta (GSTT1) gene defect. Lancet. 1996;347:295–297
  140. Felix CA, Walker AH, Lange BJ. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natal Acad Sci USA. 1998;95:13176–13181
  141. Relling MV, Yanishevski Y, Nemec J. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia. 1998;12:346–352
  142. Larson RA, Wang Y, Banerjee M. Prevalence of the inactivating609C T → polymorphism in the NAD(P)H: Quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999;94:803–807
  143. Thomsen JB, Schroder H, Kristinsson J. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells. Cancer. 1999;86:1080–1086
  144. Echlin DR, Smith LL, Rowley JD. Polymorphisms in the MLL breakpoint cluster region may predispose patients to translocations following anti-topo 2 therapy. Blood. 1999;94 (Suppl. 1):692a
  145. Sandler ES, Friedman DJ, Mustafa MM. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Cancer. 1997;79:1049–1054
  146. Anderson JE, Gooley TA, Schoch G. Stem cell transplantation for secondary acute myeloid leukemia: Evaluation of transplantation as initial therapy or following induction chemotherapy. Blood. 1997;89:2578–2585
  147. Leahey AM, Friedman DL, Bunin NJ. Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. Bone Marrow Transplantation. 1999;23:21–25
  148. Gradishar WJ, Le Beau MM, O’Laughlin R. Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood. 1992;80:2463–2470

PII: S0305-7372(00)90186-5

doi: 10.1053/ctrv.2000.0186

Cancer Treatment Reviews
Volume 26, Issue 5 , Pages 377-391 , October 2000

Article Tools